Please use this identifier to cite or link to this item:
|Title:||Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.||Authors:||Parker, Remai
Schiemann, Anja H
Stowell, Kathryn M
|Issue Date:||2017||Source:||Journal of neuromuscular diseases 2017; 4(2): 147-158||Abstract:||Central core disease and malignant hyperthermia are human disorders of skeletal muscle resulting from aberrant Ca2+ handling. Most malignant hyperthermia and central core disease cases are associated with amino acid changes in the type 1 ryanodine receptor (RyR1), the skeletal muscle Ca2+-release channel. Malignant hyperthermia exhibits a gain-of-function phenotype, and central core disease results from loss of channel function. For a variant to be classified as pathogenic, functional studies must demonstrate a correlation with the pathophysiology of malignant hyperthermia or central core disease. We assessed the pathogenicity of four C-terminal variants of the ryanodine receptor using functional analysis. The variants were identified in families affected by either malignant hyperthermia or central core disease. Four variants were introduced separately into human cDNA encoding the skeletal muscle ryanodine receptor. Following transient expression in HEK-293T cells, functional studies were carried out using calcium release assays in response to an agonist. Two previously characterized variants and wild-type skeletal muscle ryanodine receptor were used as controls. The p.Met4640Ile variant associated with central core disease showed no difference in calcium release compared to wild-type. The p.Val4849Ile variant associated with malignant hyperthermia was more sensitive to agonist than wild-type but did not reach statistical significance and two variants (p.Phe4857Ser and p.Asp4918Asn) associated with central core disease were completely inactive. The p.Val4849Ile variant should be considered a risk factor for malignant hyperthermia, while the p.Phe4857Ser and p.Asp4918Asn variants should be classified as pathogenic for central core disease.||URI:||http://hdl.handle.net/11055/265||DOI:||10.3233/JND-170210||PubMed URL:||https://www.ncbi.nlm.nih.gov/pubmed/28527222||ISSN:||2214-3599||Journal Title:||Journal of neuromuscular diseases||Type:||Journal Article|
|Appears in Collections:||Scholarly and Clinical|
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.